Related posts

TSX hits Yuletide highBOC holds rate, TSX climbsTSX flat, Wall Street declines on hot employment numbers
Investor Insights

This summary was created by AI, based on 5 opinions in the last 12 months.

Regeneron Pharmaceuticals Inc, symbol REGN-Q, has received mixed reviews from experts. Some analysts have upgraded the stock and see potential for future growth, citing a strong pipeline and momentum. Others have expressed concerns about waning momentum and delays in drug approval. However, the consensus is that the company is a quality science company with potential. The stock is currently trading at a reasonable valuation, and while there are some short-term challenges, the long-term outlook remains positive.

Consensus
Mixed
Valuation
Fair Value
BUY

He's bullish pharmas if the economy weakens. He likes it for growing organically, not buying companies, and in developing its drugs in-house or with partners. Their drug pipeline overcomes worries of their existing drugs coming off patent. Their key drug, Eylea, topped $1.04 billion in Q1 and $5.89 billion in full-year US net sales. But Roche has released a rival drug, while Eylea will come off patent in a couple years as they successfully protect their patent in court. Also, REGN just developed a new version of Eylea. Dupixent is their second-biggest drug and is performing well as well. Despite its growth, REGN trades at only 22x forward PE, and announced a $3 billion share buyback.

Pharma & Healthcare
BUY

An analyst upgraded this to $1,025, a very long way to go. He's gained 40% in this himself. It's reasonable at a 24x PE and enjoys momentum. Sees nothing to derail this.

Pharma & Healthcare
DON'T BUY

The momentum is waning, and last quarter revenue growth was only 14%. They're coming to the end of the road.

Pharma & Healthcare
BUY

Shares are down in the past 24 hours due to a delay in a drug approval. But another drug remains strong in sales, and they have double-digit in oncology drugs in trials. A great science company.

Pharma & Healthcare
WEAK BUY

A quality company. Trades at 17x. The FDA is delaying approval of a drug, but that is correctable because the issue isn't about safety or efficacy.

Pharma & Healthcare
BUY

Trades at 19x earnings, but have a huge drug pipeline.

Pharma & Healthcare
BUY
Was upgraded today. He regrets not owning it. Great managers. Owning a biotech ETF like XBI is fine for risk management. Healthcare is recession-resistant and he loves it.
Pharma & Healthcare
HOLD
She wishes that today's upgrade had come earlier. 2023 earnings will be flat, not great, but they have some new drugs will drive earnings in the future. This stock could do nothing for a while, but nothing wrong to hold it; earnings may stay flat.
Pharma & Healthcare
STRONG BUY
His favourite stock in his favourite sector. It is up 18% YTD.
Pharma & Healthcare
BUY
It trades at 13x earnings. Their pipeline is really good but was under pressure given drug pricing issues. This has outperformed the market this year. They have a strong pipeline of drugs and trades at an attractive valuation.
Pharma & Healthcare
BUY
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.
Pharma & Healthcare
HOLD
Large cap biotech. Its two franchises are dominant: macular degeneration and atopic dermatitis. One of the best at R&D. Proven ability to execute. One of the better growth profiles for next 3-5 years. Bit of volatility around reimbursement. Decent valuation. No dividend.
Pharma & Healthcare
COMMENT
They report Friday. Sells at 11x earnings. They have drugs for asthma and other illnesses.
Pharma & Healthcare
BUY
On Monday, they host an investors' event to showcase their work in RNA-based therapies and gene editing. Though it's a biotech, REGN is profitable and trades at a low PE. It trades on earnings and not future sales. If they tell a great story next week, he expects this stock to break out to an all-time high.
Pharma & Healthcare
BUY
Not only REGN, but all healthcare stocks, like Bristol-Myers and Merck, have been under pressure. REGN is a great stock and worth holding long-term.
Pharma & Healthcare
Showing 1 to 15 of 29 entries

Regeneron Pharmaceuticals Inc(REGN-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 2

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 3

Stockchase rating for Regeneron Pharmaceuticals Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Regeneron Pharmaceuticals Inc(REGN-Q) Frequently Asked Questions

What is Regeneron Pharmaceuticals Inc stock symbol?

Regeneron Pharmaceuticals Inc is a American stock, trading under the symbol REGN-Q on the NASDAQ (REGN). It is usually referred to as NASDAQ:REGN or REGN-Q

Is Regeneron Pharmaceuticals Inc a buy or a sell?

In the last year, 3 stock analysts published opinions about REGN-Q. 2 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Regeneron Pharmaceuticals Inc.

Is Regeneron Pharmaceuticals Inc a good investment or a top pick?

Regeneron Pharmaceuticals Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Regeneron Pharmaceuticals Inc.

Why is Regeneron Pharmaceuticals Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Regeneron Pharmaceuticals Inc worth watching?

3 stock analysts on Stockchase covered Regeneron Pharmaceuticals Inc In the last year. It is a trending stock that is worth watching.

What is Regeneron Pharmaceuticals Inc stock price?

On 2024-07-25, Regeneron Pharmaceuticals Inc (REGN-Q) stock closed at a price of $1085.71.